

## **Product datasheet for TL309574**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **SEC24D Human shRNA Plasmid Kit (Locus ID 9871)**

**Product data:** 

**Product Type:** shRNA Plasmids

Product Name: SEC24D Human shRNA Plasmid Kit (Locus ID 9871)

**Locus ID:** 9871

Synonyms: CLCRP2

**Vector:** pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** SEC24D - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 9871).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 01318066, NM 014822, NM 014822.1, NM 014822.2, NM 014822.3, BC035761,

BC035761.1, BC037736, NM 014822.4

UniProt ID: 094855

**Summary:** The protein encoded by this gene is a member of the SEC24 subfamily of the SEC23/SEC24

family, which is involved in vesicle trafficking. The encoded protein has similarity to yeast Sec24p component of COPII. COPII is the coat protein complex responsible for vesicle

budding from the ER. This gene product is implicated in the shaping of the vesicle, and also in cargo selection and concentration. Mutations in this gene have been associated with Cole-

Carpenter syndrome, a disorder affecting bone formation, resulting in craniofacial

malformations and bones that break easily. Alternative splicing results in multiple transcript

variants encoding different isoforms. [provided by RefSeq, Dec 2015]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).